Descripción de la empresa
Quanterix Corporation operates as a life sciences company providing specialized protein detection platforms, specifically the HD-X and SR-X instruments, across North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The firm functions within the Healthcare sector, specifically the Medical Devices industry, where it focuses on offering advanced technology for researchers to apply Simoa detection in an expanded range of applications. The company's current market capitalization stands at $168.98M, supported by an annual revenue of $138.90M and a workforce comprising 450 employees. These financial figures indicate that Quanterix maintains a mid-cap profile typical of specialized medical device manufacturers that are scaling their operational footprint while managing significant research and development expenditures.
Salud financiera
The company reported a total revenue of $138.90M over the trailing twelve months, yet this top-line figure masks a net income of $-107,150,000 and an EBITDA of $-71,927,000, revealing a cost structure where expenses significantly outweigh operational earnings before interest, taxes, depreciation, and amortization. The reported free cash flow of $-7,033,875 suggests that the company is currently burning cash, which limits its immediate financial flexibility for capital-intensive projects without external financing or internal cash generation. Analysis of the profit margins shows a gross margin of 46.8%, indicating that nearly half of the revenue remains after direct costs, while the operating margin of -48.2% and profit margin of -77.1% demonstrate substantial overhead burdens and high operational inefficiencies relative to the bottom line. The balance sheet holds $118.23M in cash against $37.24M in debt, resulting in a debt-to-equity ratio of 12.59, which implies a highly leveraged position relative to equity despite the absolute debt level being lower than cash reserves. The current ratio of 2.84 indicates a strong short-term liquidity position, suggesting the company possesses more than double the current assets needed to cover its current liabilities. However, the return on equity of -34.2% and return on assets of -13.1% reveal that management is currently destroying value rather than generating returns on the capital base employed in the business.
Evaluación de valoración
The valuation metrics present a complex picture with a trailing P/E ratio of N/A and a forward P/E of -1.88, implying that the market is pricing in a turnaround or that future earnings are expected to be negative for the near term. The price-to-book ratio of 0.57 indicates that the stock is trading below its book value, suggesting the market may be discounting the company's assets or expecting further losses to erode equity value. Alternative valuation multiples such as the price-to-sales ratio of 1.22 and an EV/EBITDA of -1.35 provide further context, showing that the company trades at a premium to its sales despite negative earnings, which is common for growth-stage biotech or medtech firms with high revenue potential but unproven profitability. The stock's trading range over the last year spans from a 52-week low of $3.36 to a 52-week high of $8.77, placing the current price in a range that reflects significant volatility and sensitivity to sector-specific news cycles. The beta of 1.32 indicates that the stock is 32% more volatile than the broader market, meaning it is expected to experience larger price swings in response to market movements compared to index constituents.
Growth & Income
Revenue growth for the company stands at 24.7% year-over-year, while earnings growth is listed as N/A due to the company's negative net income position, implying that top-line expansion is currently not translating into bottom-line profitability. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, indicating that any generated earnings are being reinvested back into the business for growth rather than distributed to shareholders. This reinvestment strategy is typical for medical device companies in the development or commercial scaling phase, where capital is directed toward R&D and market expansion to achieve sustainable profitability in the future. The overall growth and income profile is characterized by robust revenue expansion coupled with a complete lack of current income distribution, relying entirely on future operational improvements to drive returns.